Clinical Trial Update: Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting [Phase 2]

View source ↗

Summary

Phase 2 trial completed evaluating TT-173's haemostatic efficacy in reducing donor-site bleeding during skin grafting for burns and traumatic injuries.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burns
• Traumatic Injuries

Drugs mentioned

• TT-173

Snippet

Sponsor: Thrombotargets Europe S.L | Conditions: Burns, Traumatic Lesions | Phase 2 | Status: COMPLETED